Venture Partner, 5AM Ventures
June H. Lee, MD FACCP joined 5AM as a Venture Partner in 2022. Dr. Lee is a physician-scientist with over 20 years in the biotechnology and pharmaceutical industry. Currently, she is the CEO of a 5AM seeded 4:59AM NewCo. Prior to 5AM, she was the Founder and CEO of Esker Therapeutics (Alumis). She previously served as Executive Vice President, Chief Development Officer, and Chief Operating Officer of MyoKardia where she built and led a world-class development organization that was acquired by Bristol Myers Squibb for $13.1 billion in November 2020. The lead program at MyoKardia, mavacamten, was recently approved by the FDA for use in obstructive hypertrophic cardiomyopathy patients as the first precision therapy in this indication.
Prior to MyoKardia, Dr. Lee was Professor of Medicine at UCSF School of Medicine, where she served as Director of Translational Research and built the Catalyst Program, an internal accelerator for early-stage technologies. As the therapeutic area head at Genentech, Dr. Lee led early clinical development programs in cardiovascular and metabolic diseases, infectious diseases, and respiratory diseases.
Dr. Lee serves on numerous boards in the healthcare industry including the Advisory Board for Johns Hopkins University Center for Therapeutic Translation, the Board of Directors for Tenaya Therapeutics, AbiVax Therapeutics, CinCor Pharma (acquired by Astra Zeneca 2023), Eledon Pharmaceuticals Inc. and GenEdit, and is a member of the Scientific Advisory Board for Foresite Labs. Dr. Lee received her undergraduate degree in chemistry at Johns Hopkins University, earned her medical degree at the School of Medicine at University of California, Davis, and completed her clinical training in internal medicine and pulmonary and critical care at UCLA and UCSF. Dr. Lee is based in the San Francisco, CA office.